基于综合生物信息学分析,识别和验证与质母细胞瘤中泰莫佐洛米德耐药性相关的关键基因
Jun Hu1, Jingyan Yang2, Na Hu1
1The Third Affiliated Hospital of Beijing University of Chinese Medicine, Beijing, China.
Iranian journal of biotechnology
|April 14, 2025
概括
三个基因,PITX1,TNFRSF11B和IGFBP2,被确定为质母细胞瘤 (GBM) 中的特莫索洛米德 (TMZ) 耐药性的关键驱动因素. 它们的差异表达与预后不佳相关,为GBM治疗和诊断提供了潜在的生物标志物.
科学领域:
- 神经瘤学神经瘤学
- 基因组学就是基因组学.
- 生物信息学是一种生物信息学.
背景情况:
- 质母细胞瘤 (GBM) 是一种具有有限治疗选择的侵袭性脑癌.
- 泰莫佐洛米德 (TMZ) 耐药性在GBM管理中构成了重大临床挑战.
- 识别与TMZ耐药性相关的基因对于开发新疗法和预后工具至关重要.
研究的目的:
- 确定与GBM中TMZ耐药性相关的关键基因.
- 评估这些基因在GBM患者的预后价值.
- 探索它们作为诊断生物标志物或治疗点的潜力.
主要方法:
- 对GEO和CGGA数据集的生物信息学分析.
- 针对预后相关模块的权重基因联合表达网络分析 (WGCNA).
- 机器学习算法用于枢纽基因识别.
- 使用RT-qPCR和西式涂抹在TMZ耐药细胞系中的验证.
主要成果:
- 在GBM和正常对照组之间鉴定了769个差异表达基因 (DEG).
- 优先考虑PITX1,TNFRSF11B和IGFBP2作为关键基因与TMZ耐药性相关.
- 在体外证实了这些基因的差异表达及其与不良临床特征和免疫透的关联.
结论:
- PITX1,TNFRSF11B和IGFBP2是GBM TMZ耐药性的关键基因.
- 这些基因是GBM患者的宝贵预后生物标志物.
- 它们代表了GBM的潜在诊断生物标志物和治疗点.
更多相关视频
05:29A Rapid Screening Workflow to Identify Potential Combination Therapy for GBM using Patient-Derived Glioma Stem Cells
Published on: March 28, 2021
2.7K
07:47Author Spotlight: Unveiling Transmembrane Protein Family-Related Markers in Gastric Cancer and Implications for Targeted Therapies
Published on: September 15, 2023
1.4K
相关概念视频
01:05Cancer-Critical Genes II: Tumor Suppressor Genes
Genes usually encode proteins necessary for the proper functioning of a healthy cell. Mutations can often cause changes to the gene expression pattern, thereby altering the phenotype.
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
When the function of certain critical genes, especially those involved in cell cycle regulation and cell growth signaling cascades, gets disrupted, it upsets the cell cycle progression. Such cells with unchecked cell cycles start proliferating uncontrollably and eventually develop into tumors.
Such genes that act...
01:11Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase
Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...
01:29Pharmacogenomics: Identification of New Drug Targets
Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...